Clinical Trials: Emerging therapeutic strategies targeting GPNMB, including CAR-T cell approaches for glioma and bispecific antibodies for NSCLC, hold potential to redefine cancer treatment paradigms. This evidence concerns the gene GPNMB and non-small cell lung carcinoma.